A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia
© 2022 by The American Society of Hematology..
Excessive intravascular release of lysed cellular contents from damaged red blood cells (RBCs) in patients with sickle cell anemia (SCA) can activate the inflammasome, a multiprotein oligomer promoting maturation and secretion of proinflammatory cytokines, including interleukin-1β (IL-1β). We hypothesized that IL-1β blockade by canakinumab in patients with SCA would reduce markers of inflammation and clinical disease activity. In this randomized, double-blind, multicenter phase 2a study, patients aged 8 to 20 years with SCA (HbSS or HbSβ0-thalassemia), history of acute pain episodes, and elevated high-sensitivity C-reactive protein >1.0 mg/L at screening were randomized 1:1 to received 6 monthly treatments with 300 mg subcutaneous canakinumab or placebo. Measured outcomes at baseline and weeks 4, 8, 12, 16, 20, and 24 included electronic patient-reported outcomes, hospitalization rate, and adverse events (AEs) and serious AEs (SAEs). All but 1 of the 49 enrolled patients were receiving stable background hydroxyurea therapy. Although the primary objective (prespecified reduction of pain) was not met, compared with patients in the placebo arm, patients treated with canakinumab had reductions in markers of inflammation, occurrence of SCA-related AEs and SAEs, and number and duration of hospitalizations as well as trends for improvement in pain intensity, fatigue, and absences from school or work. Post hoc analysis revealed treatment effects on weight, restricted to pediatric patients. Canakinumab was well tolerated with no treatment-related SAEs and no new safety signal. These findings demonstrate that the inflammation associated with SCA can be reduced by selective IL-1β blockade by canakinumab with potential for therapeutic benefits. This trial was registered at www.clinicaltrials.gov as #NCT02961218.
| Errataetall: |
CommentIn: Blood. 2022 Apr 28;139(17):2578-2580. - PMID 35482344 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:139 |
|---|---|
| Enthalten in: |
Blood - 139(2022), 17 vom: 28. Apr., Seite 2642-2652 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rees, David C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
37CQ2C7X93 |
|---|
| Anmerkungen: |
Date Completed 02.05.2022 Date Revised 07.06.2022 published: Print ClinicalTrials.gov: NCT02961218 CommentIn: Blood. 2022 Apr 28;139(17):2578-2580. - PMID 35482344 Citation Status MEDLINE |
|---|
| doi: |
10.1182/blood.2021013674 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337581428 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337581428 | ||
| 003 | DE-627 | ||
| 005 | 20231225234739.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/blood.2021013674 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1125.xml |
| 035 | |a (DE-627)NLM337581428 | ||
| 035 | |a (NLM)35226723 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rees, David C |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.05.2022 | ||
| 500 | |a Date Revised 07.06.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT02961218 | ||
| 500 | |a CommentIn: Blood. 2022 Apr 28;139(17):2578-2580. - PMID 35482344 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 by The American Society of Hematology. | ||
| 520 | |a Excessive intravascular release of lysed cellular contents from damaged red blood cells (RBCs) in patients with sickle cell anemia (SCA) can activate the inflammasome, a multiprotein oligomer promoting maturation and secretion of proinflammatory cytokines, including interleukin-1β (IL-1β). We hypothesized that IL-1β blockade by canakinumab in patients with SCA would reduce markers of inflammation and clinical disease activity. In this randomized, double-blind, multicenter phase 2a study, patients aged 8 to 20 years with SCA (HbSS or HbSβ0-thalassemia), history of acute pain episodes, and elevated high-sensitivity C-reactive protein >1.0 mg/L at screening were randomized 1:1 to received 6 monthly treatments with 300 mg subcutaneous canakinumab or placebo. Measured outcomes at baseline and weeks 4, 8, 12, 16, 20, and 24 included electronic patient-reported outcomes, hospitalization rate, and adverse events (AEs) and serious AEs (SAEs). All but 1 of the 49 enrolled patients were receiving stable background hydroxyurea therapy. Although the primary objective (prespecified reduction of pain) was not met, compared with patients in the placebo arm, patients treated with canakinumab had reductions in markers of inflammation, occurrence of SCA-related AEs and SAEs, and number and duration of hospitalizations as well as trends for improvement in pain intensity, fatigue, and absences from school or work. Post hoc analysis revealed treatment effects on weight, restricted to pediatric patients. Canakinumab was well tolerated with no treatment-related SAEs and no new safety signal. These findings demonstrate that the inflammation associated with SCA can be reduced by selective IL-1β blockade by canakinumab with potential for therapeutic benefits. This trial was registered at www.clinicaltrials.gov as #NCT02961218 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a canakinumab |2 NLM | |
| 650 | 7 | |a 37CQ2C7X93 |2 NLM | |
| 700 | 1 | |a Kilinc, Yurdanur |e verfasserin |4 aut | |
| 700 | 1 | |a Unal, Selma |e verfasserin |4 aut | |
| 700 | 1 | |a Dampier, Carlton |e verfasserin |4 aut | |
| 700 | 1 | |a Pace, Betty S |e verfasserin |4 aut | |
| 700 | 1 | |a Kaya, Banu |e verfasserin |4 aut | |
| 700 | 1 | |a Trompeter, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Odame, Isaac |e verfasserin |4 aut | |
| 700 | 1 | |a Mahlangu, Johnny |e verfasserin |4 aut | |
| 700 | 1 | |a Unal, Sule |e verfasserin |4 aut | |
| 700 | 1 | |a Brent, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Grosse, Regine |e verfasserin |4 aut | |
| 700 | 1 | |a Fuh, Beng R |e verfasserin |4 aut | |
| 700 | 1 | |a Inusa, Baba P D |e verfasserin |4 aut | |
| 700 | 1 | |a Koren, Ariel |e verfasserin |4 aut | |
| 700 | 1 | |a Leblebisatan, Goksel |e verfasserin |4 aut | |
| 700 | 1 | |a Levin, Carina |e verfasserin |4 aut | |
| 700 | 1 | |a McNamara, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Meiser, Karin |e verfasserin |4 aut | |
| 700 | 1 | |a Hom, Douglas |e verfasserin |4 aut | |
| 700 | 1 | |a Oliver, Stephen J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood |d 1946 |g 139(2022), 17 vom: 28. Apr., Seite 2642-2652 |w (DE-627)NLM000014761 |x 1528-0020 |7 nnns |
| 773 | 1 | 8 | |g volume:139 |g year:2022 |g number:17 |g day:28 |g month:04 |g pages:2642-2652 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/blood.2021013674 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 139 |j 2022 |e 17 |b 28 |c 04 |h 2642-2652 | ||